Search Results

You are looking at 101 - 110 of 265 items for :

  • "expectancy" x
  • Refine by Access: All x
Clear All
Full access

If We Build It, They Will Come: Rethinking Some Assumptions About Screening and Intervening for Distress

Steven C. Palmer

might influence their needs and abilities to engage in intervention. In Schuurhuizen et al, patients had metastatic colorectal cancer with a life expectancy of >3 months—a particularly vulnerable population. More than 20% of patients died during the

Full access

Impact of Age and Comorbidity in Myelodysplastic Syndromes

Reinhard Stauder, Thomas Nösslinger, Michael Pfeilstöcker, Wolfgang R. Sperr, Friedrich Wimazal, Otto Krieger, and Peter Valent

. Malcovati L Porta MG Pascutto C . Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making . J Clin Oncol 2005 ; 23 : 7594 – 7603 . 6. Malcovati L Della

Full access

The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines

Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro, and Gary H. Lyman

drugs . Cigna Government Services. Available at : . Accessed August 15, 2008 . 39. Malcovati L Porta MG Pascutto C . Prognostic factors and life expectancy in myelodysplastic

Full access

NCCN Task Force: Transfusion and Iron Overload in Patients With Myelodysplastic Syndromes

Peter L. Greenberg, Cynthia K. Rigsby, Richard M. Stone, H. Joachim Deeg, Steven D. Gore, Michael M. Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Paul J. Shami, and Rashmi Kumar

transplantation in patients with de novo myelodysplastic syndrome (MDS) . Biol Blood Marrow Transplant 2008 ; 14 : 1217 – 1225 . 37 Malcovati L Porta MG Pascutto C . Prognostic factors and life expectancy in myelodysplastic syndromes classified

Full access

Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes

Rafael Bejar

Optimizing Therapy for Individual Patients Myelodysplastic syndromes (MDS) are a group of bone marrow failure disorders characterized by ineffective hematopoiesis. For many patients with lower-risk MDS, life expectancy can exceed 5 years. However

Full access

Cancer Clinical Trial Enrollment: OK Doc, but What’s in It for Me?

Henry Soo-Min Park

with an unselected cohort treated off-trial (some of whom may have been deemed ineligible for trial enrollment due to poor functional status or life expectancy, or who were treated at low-volume facilities without comprehensive multidisciplinary

Full access

Appropriate Use of Imaging to Detect Primary, Second Primary, and Recurrent Breast Cancer

Bethany L. Niell

optimal imaging strategies for early detection of primary, second primary, and metastatic breast cancers, and then tailor those surveillance strategies based on risk of recurrence, life expectancy, and comorbid conditions; develop systems-based approaches

Full access

Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?

Alejandro Garcia-Horton and Jeffrey H. Lipton

and prevalence increasing due to prolonged survival. 2 , 3 Life expectancy has approached that of the general population, with 5-year survival only slightly lower in patients with CML. 4 This benefit is observed in all age groups, but especially in

Full access


clinical trials when appropriate. Prostate cancer is a complex disease; fortunately there is a dearth of sound data to support treatment recommendations. NCCN’s Guidelines for Patients: Prostate Cancer cover several variables (including life expectancy

Full access

Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines

James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas Farrington, Celestia S. Higano, Eric Mark Horwitz, Philip W. Kantoff, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Stan Rosenfeld, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Przemyslaw Twardowski, Patrick C. Walsh, Maria Ho, and Dorothy A. Shead

and overtreatment of early tumors is the subject of ongoing controversy fueled by large screening studies. 2 – 5 Depending on the disease characteristics and the patient’s life expectancy and personal preference, active surveillance may be a viable